Adalimumab-adaz Injection — FDA Drug Shortage

To Be Discontinued — Sandoz Inc.

The FDA lists a drug shortage record for Adalimumab-adaz Injection (injection) from Sandoz Inc. with status To Be Discontinued. The shortage was first posted on Jan 13, 2026.

Shortage details

Status
To Be Discontinued
Company
Sandoz Inc.
Package NDC
61314-473-64
Dosage Form
Injection
Presentation
Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64)
Initial Posting
Jan 13, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.